CLONING AND CHARACTERIZATION OF THE HEPATITIS G VIRUS

美国国立卫生研究院(NIH)对输血的研究- 相关肝炎和疾病控制与预防中心 社区获得性肝炎预防(CDC)报告显示，10 到20%的观察到的肝炎病例无法解释 已知的甲型、乙型、丙型、丁型和戊型肝炎病毒 另一种或多种人类肝炎制剂的存在， 建立了一项合作研发协议 美国国立卫生研究院输血医学部与Genelabs Technologies，Inc.和CDC。可疑的临床材料被送到 Genelabs基因，经逆转录后扩增 不依赖序列的单引物扩增及克隆 利用gt11表达载体，转化到大肠杆菌中。一个克隆人 对基因库来说是新的，而且是外源的 杂交分析。可以从克隆中恢复该试剂 来源，并被证明是一种有别于其他成员的黄病毒 那个家庭的一员。它有大约25%的同源性 丙型肝炎病毒(HCV)。聚合酶链式反应检测 并对临床资料进行了筛选。代理， 暂定为丙型肝炎病毒，与大约20 输血型肝炎和社区相关性肝炎的比例 与之前公认的病原体无关，但其因果关系 在肝炎的发展中所起的作用尚未确定。HGV 在1%到2%的献血者中发现，并已被证明是 通过有关联的供受者样本传播的输血。 总之，丙型肝炎病毒是黄病毒家族的一个新成员 在普通人群中流行，并通过输血 可传染的。需要进一步的研究才能确定它的疾病 负担，特别是确定它是否会导致肝炎或 仅与肝炎有关，因为共享传播 与另一名目前无法检测到的特工(S)的模式。

Studies at the National Institutes of Health (NIH) of transfusion- associated hepatitis and at the Centers for Disease Control and Prevention (CDC) of community-acquired hepatitis indicated that 10 to 20 percent of observed hepatitis cases could not be accounted for by the known hepatitis viruses: A, B, C, D, and E. To investigate the existence of an additional agent or agents of human hepatitis, a collaborative research and development agreement was established between the Department of Transfusion Medicine, NIH; Genelabs Technologies, Inc.; and CDC. Suspect clinical materials were sent to Genelabs and were amplified following reverse transcription by sequence independent single primer amplification and then cloned into Escherichia coli, using a gt11 expression vector. A clone was identified that was novel to the gene bank and exogenous by hybridization assays. The agent could be recovered from the cloning source and was shown to be a flavivirus distinct from other members of that family. It had approximately 25 percent homology with hepatitis C virus (HCV). A polymerase chain reaction assay was developed, and clinical materials were screened. The agent, tentatively designated HCV, is associated with approximately 20 percent of transfusion hepatitis and community-associated hepatitis that are unrelated to previously recognized agents, but its causal role in the development of hepatitis has not been established. HGV is found in 1 to 2 percent of blood donors and has proved to be transfusion transmitted by linked donor-recipient samples. In summary, HCV is a new member of the flaviviridae family that is prevalent in the general population and is transfusion transmissible. Further studies are required to establish its disease burden and, particularly, to define whether it causes hepatitis or is merely associated with hepatitis because of shared transmission patterns with another agent(s) that is currently undetectable.